Ocugen Inc

-0.14 (-2.39%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.04B
Current PEN/A
Forward PE 3.13
2yr Forward PE 1.55
See more stats
Estimates Current Quarter
Revenue$39.04 Million
Adjusted EPS$0.19
See more estimates
10-Day MA$6.25
50-Day MA$8.58
200-Day MA$2.72
See more pivots

Ocugen Inc Stock, NASDAQ:OCGN

263 Great Valley Parkway, Suite 160, Malvern, Pennsylvania 19355
United States of America
Phone: +1.484.328.4701
Number of Employees: 15


Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, and COVAXIN. The firm's Modifier Gene Therapy Platform engages to address retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.